New tuberculosis (TB) vaccines are anticipated to become available starting in 2029, offering a new and key tool in the global fight against the deadly disease. These new vaccines are expected to significantly impact low- and middle-income countries, regions where the burden of TB is disproportionately high. Gavi, the Vaccine Alliance, notes the stark reality that countries it supports are estimated to account for 77% of all TB deaths worldwide, showing the urgent and profound need for new preventive measures in these vulnerable populations. The impending introduction of these vaccines aims to dramatically reduce both mortality and morbidity in high-burden countries, with the potential to save millions of lives and transform public health outcomes.
The Urgent Need for Innovation
The global health community faces a significant challenge with tuberculosis. Globally, 10.7 million tuberculosis cases and 1.2 million tuberculosis deaths were recorded in 2024, demonstrating the persistent and widespread impact of the disease. Despite its prevalence, the only currently licensed vaccine, Bacille Calmette-Guérin (BCG), has been in use for over 100 years. While BCG offers some protection, particularly against severe forms of TB in children, its efficacy against pulmonary TB in adolescents and adults, which is the primary driver of transmission, is limited. Consequently, new vaccines are being developed with the specific aim of preventing infectious pulmonary TB disease among adolescents and adults, addressing a critical gap in current prevention strategies. This focus on preventing infectious forms of the disease among these age groups is expected to have a substantial impact on reducing transmission rates.
Projected Impact and Demand
The introduction of new tuberculosis vaccines could help save an estimated 7.3 million lives between 2030 and 2050, marking a monumental step forward in global health. These projections show the transformative potential of these new preventive tools. The anticipated demand for these vaccines among low-income and middle-income countries is substantial, projected to reach, on average, 85 million vaccination courses annually. This high demand reflects the immense need and the potential for widespread adoption in regions most affected by TB. Preliminary modeling conducted by the London School of Hygiene & Tropical Medicine underpins these significant projections. This detailed modeling is based on a strategic vaccination scenario that targets high-risk populations and adolescents, aiming to maximize the public health impact of the new vaccines.
Gavi's Strategy for Rollout
Gavi, the Vaccine Alliance, states emphatically that immediate action is necessary to prepare both governments and vaccine manufacturers for the impending arrival of these new tuberculosis vaccines. The organization warns that proactive engagement is critical to ensure a smooth and equitable rollout. Gavi's full Roadmap identifies several potential risks to successful deployment, including policy limitations that could hinder access, insufficient financing to procure and distribute vaccines, and uncertainties within the supply chain that could disrupt availability. To mitigate these challenges and ensure broad access, Gavi's objectives for this key rollout include ensuring a sufficient, timely, affordable, and sustainable supply of vaccines. Beyond supply, the alliance also aims to support widespread uptake of these new vaccines through strong implementation strategies and to encourage a competitive pipeline of future vaccine candidates, fostering continuous innovation in TB prevention.
Ensuring Future Access and Economic Benefits
The successful introduction and widespread use of these new vaccines could unlock substantial economic benefits. Specifically, they could generate up to US$135 billion in economic benefits across low- and middle-income countries, reflecting improved health outcomes, increased productivity, and reduced healthcare costs. The first of these new candidate vaccines is projected to secure regulatory approval by the end of this decade, paving the way for their eventual deployment. This regulatory milestone will be a critical step towards making these life-saving interventions available to populations most in need. Gavi's proactive approach, focusing on market shaping and preparedness, is designed to ensure that when these vaccines become available, they can reach those who stand to benefit most, thereby accelerating progress towards a world free from tuberculosis.
